Previous Close | 3.7700 |
Open | 3.8800 |
Bid | 3.8000 x 900 |
Ask | 3.9100 x 1300 |
Day's Range | 3.8000 - 4.1500 |
52 Week Range | 3.0300 - 22.5000 |
Volume | |
Avg. Volume | 97,375 |
Market Cap | 19.528M |
Beta (5Y Monthly) | 6.34 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.9980 |
Earnings Date | May 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 28.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for APVO
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to DateCohort 3 Monotherapy Patient Achieved Bone Marrow Complete RemissionCompany Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable and on APVO436 After 18 Months of TreatmentSEATTLE, WA / ACCESSWIRE / June 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel im
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended March 31, 2022.
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant DiseaseSEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the presentation of preclinical data for APVO442 in a poster session at the American